The grant will further the development of Accuro 3S, designed for image-guided regional anesthesia, to broaden access to opioid-sparing analgesia for hip fracture pain.

RIVANNA®, developers of imaging-based medical solutions, announced that they have received funding totaling $30.5 million over 39 months from early execution of an option by the Biomedical Advanced Research and...

Two-year export program provides resources to support international business expansion.

As a domain expert in applications of diagnostic ultrasound imaging, Dr. Sheeran will lead projects primarily focused on Accuro XV CADe/x algorithm development and testing at RIVANNA.

RIVANNA to invest $260,000 to renovate facility and more than double its workforce.

BOMImed is a choice distribution partner for Rivanna as its focus is within the fields of anesthesia and critical care, with company resources dedicated to providing the highest level of service.

The developers of imaging-based medical solutions have received a contract from the Biomedical Advanced Research and Development Authority (BARDA) for the design and development of a computer-aided 3D fracture detection...

Rivanna’s international sales of the Accuro device generated 73% of their Quarter 2 revenue, indicating the success of their expanding global distribution footprint.

Rivanna®, developers of world-first imaging-based medical solutions, today announced the results of a recent randomized controlled trial.

Rivanna announced they have entered into a partnership with Tri-anim Health Services to represent and distribute the Accuro® portfolio of products in the United States.

Rivanna announces the market introduction of Accuro Second Generation, combining innovative thoracic spine functionality with its groundbreaking introductory system.